Guard Therapeutics: Uncertain future - Redeye

Redeye returns with a new note after gaining more insights from Monday’s webcast. Following the failure of the phase IIb study POINTER, we lower our valuation substantially and now ground our valuation scenarios on strategic alternatives.

Länk till analysen i sin helhet: https://www.redeye.se/research/1134270/guard-therapeutics-uncertain-future?utm_source=finwire&utm_medium=RSS